To the Editor In the Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early Stage Non–Small Cell Lung Cancer (MISSILE-NSCLC) trial, Palma and colleagues1 reported on a well-executed phase 2 trial of stereotactic ablative radiotherapy (SABR) followed by definitive resection in early-stage NSCLC. Surprisingly, this study showed that the pathological complete response (pCR) rate was only 60% at 10 weeks after SABR. This is substantially lower than the assumed pCR rate and challenges us to revisit some commonly held assumptions about SABR.
Ko EC, Vanpouille-Box C, Formenti SC. Analysis of Pathologic Complete Response 10 Weeks After Radiotherapy—A Radiobiological Sin. JAMA Oncol. 2019;5(9):1365. doi:10.1001/jamaoncol.2019.1882
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: